Download PDF
Thromb Haemost 1982; 47(02): 132-135
DOI: 10.1055/s-0038-1657147
Original Article
Schattauer GmbH Stuttgart

A Comparison of Acylated Streptokinase-Plasminogen Complex and Streptokinase in Healthy Volunteers

C V Prowse
The Edinburgh and South-East Scotland Blood Transfusion Service, Edinburgh, U. K.
,
V Hornsey
The Edinburgh and South-East Scotland Blood Transfusion Service, Edinburgh, U. K.
,
C V Ruckley
*   The Department of Clinical Surgery, Royal Infirmary, Edinburgh, U. K.
,
F E Boulton
The Edinburgh and South-East Scotland Blood Transfusion Service, Edinburgh, U. K.
› Author Affiliations
Further Information

Publication History

Received 21 December 1981

Accepted 09 February 1982

Publication Date:
13 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The in vivo effects on the fibrinolytic and coagulation system of infusing acylated streptokinase-plasminogen complex (BRL 26921; 5, 7 and 12 mg) or streptokinase (250,000 u) were determined in healthy male volunteers. While this dose of streptokinase resulted in depletion of plasminogen and antiplasmin, and in some cases of fibrinogen and coagulation factors V and VIII, the equivalent 7 mg dose of BRL 26921 had little effect on these parameters. 12 mg BRL 26921 had some systemic effects on the fibrinolytic system. For initial clinical studies a dose of 10 mg BRL 26921 would seem appropriate.

Both drugs induced an anamnestic rise in streptokinase antibody, whereas no change in liver function tests were observed. A delayed mild febrile reaction was observed in some subjects following infusion of streptokinase or BRL 26921. Clinical, laboratory, and subjective monitoring revealed no other adverse effects with either drug.

Key words

Fibrinolysis - Streptokinase - Plasminogen
 

  • References

  • 1 Nilsson IM, Olow B. Fibrinolysis induced by streptokinase in man. Acta Chir Scand 1962; 123: 247-266
    PubMedGoogle Scholar
  • 2 Collen D, Verstraete M. Alpha-2-antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy. Thromb Res 1979; 14: 631-639
    CrossrefPubMedGoogle Scholar
  • 3 Verstraete M, Vermylen J, Schetz J. Biochemical changes noted during intermittent administration of Streptokinase. Thromb Haemostas 1978; 39: 61-68
    PubMedGoogle Scholar
  • 4 Verstraete M, Vermylen J, Holleman W, Barlow GH. Biological effects of the administration of an equimolar streptokinase-plasminogen complex in man. Thromb Res 1977; 11: 227-236
    CrossrefPubMedGoogle Scholar
  • 5 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 6 Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acylenzymes: a new approach to thrombolytic therapy. Nature 1981; 290: 505-508
    CrossrefPubMedGoogle Scholar
  • 7 Prowse CV, Cash JD. The use of factor IX concentrates in man: a nine-year experience of Scottish concentrates in the south-east of Scotland. Br J Haematol 1981; 47: 91-104
    CrossrefPubMedGoogle Scholar
  • 8 Prowse CV, Douglas JG, Forrest JAH, Forsling ML. Haemostatic effects of lysine vasopressin and triglycyl lysine vasopressin infusion in patients with cirrhosis. Eur J Clin Invest 1980; 10: 49-54
    CrossrefPubMedGoogle Scholar
  • 9 Collen D, De Cock F, Cambiaso CL, Masson P. A latex agglutination test for the rapid quantitative estimation of the plasmin-antiplasmin complex in human plasma. Eur J Clin Invest 1977; 7: 21-26
    CrossrefPubMedGoogle Scholar
  • 10 Edy J, De Cock F, Collen D. Inhibition of plasmin by normal and antiplasmin-depleted human plasma. Thromb Res 1976; 8: 513-518
    CrossrefPubMedGoogle Scholar